November 13, 2013 |
[Eds: Please visit Bill’s new blog at http://liveherpesvaccine.com/]
David Knipe, Lynda Morrison, and Jeffrey Cohen are three of the principal scientists who have been involved in research over the past 15 years that has brought the HSV-2 ACAM-529 vaccine to a Phase I Clinical Trial. Sanofi Pasteur is the company that has backed / sponsored the ACAM-529 vaccine, and Sanofi Pasteur will presumably be bringing the HSV-2 ACAM-529 vaccine to market if it succeeds in all phases of human clinical trials.
Dr. Knipe was kind enough to share the following information with me earlier today, which I pass along for those who may be interested in enrolling in the ACAM-529 vaccine clinical trial.
Here are the links for the start of the HSV5-29 trial for your blog.
If people want to write to me about the trial (I am not conducting it though), they can write to me at this address: firstname.lastname@example.org
David, I believe that I speak for millions of genital herpes sufferers worldwide when I say thank you for your dedication and perseverance over the past 15 years, which has brought ACAM-529 from a HSV-2 vaccine concept to the first human clinical trial of a HSV-2 viral vaccine that has real potential to be a game-changer.
You have my best wishes and hopes that the trials of the HSV-2 ACAM-529 vaccine represent a turning point in the development of a HSV-2 genital herpes vaccine that is both safe and effective.
– Bill H.